| Multiple Myeloma |
1 |
1 |
| Grant |
0 |
0.51 |
| Otolaryngology |
0 |
0.32 |
| Toxicology |
0 |
0.3 |
| Leukemia |
0 |
0.29 |
| Risk Evaluation and Mitigation Strategies |
0 |
0.29 |
| Upper Respiratory Tract Infection |
0 |
0.24 |
| Xerostomia |
0 |
0.24 |
| Biologic Therapy |
0 |
0.23 |
| Dentistry and Oral Health |
0 |
0.23 |
| Patient Safety |
0 |
0.23 |
| Biomedical Technology |
0 |
0.17 |
| Blood |
0 |
0.17 |
| Cancer |
0 |
0.17 |
| Cytokines |
0 |
0.17 |
| Dermatoses |
0 |
0.17 |
| Dysgeusia |
0 |
0.17 |
| Dysphagia |
0 |
0.17 |
| Fatigue |
0 |
0.17 |
| Fever |
0 |
0.17 |
| Food and Drug Administration (FDA) |
0 |
0.17 |
| Monoclonal Antibody |
0 |
0.17 |
| Mouth |
0 |
0.17 |
| Nail |
0 |
0.17 |
| Neurotoxicity |
0 |
0.17 |
| Orphan Drugs |
0 |
0.17 |
| Pain |
0 |
0.17 |
| Proteasome Inhibitor |
0 |
0.17 |
| Receptors |
0 |
0.17 |
| Refractory |
0 |
0.17 |
| Respiratory Tract |
0 |
0.17 |
| Xeroderma |
0 |
0.17 |
| Revenue and Practice Management |
0 |
0.14 |
| Diarrhea |
0 |
0.09 |
| Healthcare and Medical Technology |
0 |
0.09 |
| Pain Management |
0 |
0.09 |